Multicentre gene therapy for OTOF-related deafness followed up to 2.5 years

Beyond the Implant: The Rise of Biological Hearing Restoration

For decades, cochlear implantation has been the gold standard for treating profound congenital deafness. However, a paradigm shift is occurring. We are moving from mechanical stimulation of the auditory nerve to the biological restoration of the ear’s own cellular machinery.

At the center of this revolution is the OTOF gene, which encodes a protein called otoferlin. This protein is not just a structural component; it is a critical driver of synaptic exocytosis and vesicle replenishment at the inner hair cells (IHCs) of the cochlea.

The Science of DFNB9 and the OTOF Mutation

DFNB9 is a form of autosomal recessive profound prelingual deafness. It occurs when biallelic pathogenic variants in the OTOF gene result in a deficient or dysfunctional otoferlin protein. Because this protein is essential for signal transmission, its absence means that auditory sensory cells cannot communicate with the auditory nerve.

Recent genetic research has highlighted the prevalence of these mutations across various populations, including studies in Japan, Pakistan, and China, emphasizing that OTOF-related hearing loss is a global challenge requiring a targeted molecular solution.

AAV-Mediated Gene Therapy: From Mice to Humans

The transition from theory to therapy began with adeno-associated virus (AAV) vectors. Preclinical studies using Otof-deficient mice demonstrated that transferring Otof cDNA into the cochlea could restore hearing. This success paved the way for human clinical trials using AAV1-hOTOF.

The most recent advancements have moved beyond unilateral treatment to bilateral gene therapy. By administering the transgene to both ears, researchers are aiming to restore binaural hearing, which is essential for sound source localization—a capability that is nearly impossible to achieve with traditional implants.

Real-World Results: Restoring Speech and Sound

The efficacy of binaural AAV gene therapy has been observed in pediatric patients with DFNB9. In a single-arm trial of five children, the results were transformative:

• Hearing Thresholds: Patients who started with auditory brainstem response (ABR) thresholds greater than 95 dB saw significant restoration. Thresholds improved to ranges such as 58 dB (Patient 1), 50-85 dB (Patient 2), 50-55 dB (Patient 3), 75-78 dB (Patient 4), and 63 dB (Patient 5).
• Functional Gains: All five patients experienced a restoration of speech perception and the ability to localize the source of sounds.
• Safety Profile: The therapy was generally safe with no dose-limiting toxicity or serious adverse events. The most common side effects were limited to increased cholesterol levels and increased lymphocyte counts.

Gene Therapy vs. Cochlear Implantation: The Future Landscape

The emergence of AAV-OTOF therapy introduces a critical comparison: biological restoration versus mechanical substitution. While cochlear implants bypass the damaged hair cells to stimulate the nerve directly, gene therapy seeks to fix the hair cells themselves.

The potential future trend points toward a hybrid approach where genetic testing determines the primary intervention. For those with specific OTOF mutations, biological restoration may offer a more “natural” auditory experience, including better frequency resolution and spatial awareness, which are often limited in cochlear implant users.

As we refine these techniques, the focus is shifting toward optimizing the delivery of the human OTOF transgene to ensure long-term stability and efficacy in the mature cochlea.

Frequently Asked Questions